NovaSom, Inc.

NovaSom, Inc. is a pioneering biotechnology startup founded in 1992 that specializes in providing diagnostic services for obstructive sleep apnea (OSA) through home testing and evaluation. The company has developed the first FDA-cleared device designed for unattended, unassisted patient use for the diagnosis of sleep apnea, with clinically proven equivalence to conventional polysomnography (PSG). NovaSom collaborates with physicians, private insurers, and government and public health organizations to address the issue of undiagnosed sleep apnea, which leads to increased healthcare costs. The company's ultimate goal is to improve the healthcare and quality of life for individuals impacted by sleep disorders by promoting adherence to prescribed therapies.

The most recent investment in NovaSom was a $12.50M Debt Financing round on 01 January 2018, in which Armentum Partners participated as the investors. This funding signifies potential growth opportunities and underscores investor confidence in the company's vision and capabilities.

NovaSom's commitment to addressing the unmet needs in sleep apnea diagnosis and treatment, along with their innovative approach, positions them as a promising player in the biotechnology space. The company's ability to secure significant investment, evidenced by the recent funding round, reflects the recognition of their potential impact on healthcare and the market. As such, NovaSom presents an intriguing investment prospect for venture capitalists seeking opportunities in the biotechnology sector.